Research Article

Long Noncoding RNA SNHG12 Promotes Prostate Tumor Occurrence and Progression via AKT Regulation

Zheng Chen,1 Tao Qi,2 Xiao-ping Qin,1 Jue Wang,3 Zhang-sen Huang,2 Xiao-yong Hu,4 Guo Chen,1 Li-jun Qu1,1 and Yu-min Zhuo1

1Department of Urology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China
2Department of Infertility and Sexual Medicine, The Third Affiliated Hospital of Jinan University, Guangzhou 510630, China
3Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
4Department of Urology, The Sixth People’s Hospital Affiliated of Shanghai Jiaotong University, Shanghai 200000, China

Correspondence should be addressed to Li-jun Qu; 13068856660@163.com and Yu-min Zhuo; tzhuyumin@126.com

Zheng Chen, Tao Qi, and Xiao-ping Qin contributed equally to this work.

Received 18 September 2020; Revised 5 November 2020; Accepted 25 November 2020; Published 22 December 2020

Academic Editor: Zhenbo Xu

Copyright © 2020 Zheng Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The small nucleolar RNA host gene 12 (SNHG12) has been reported to play an important role in the tumorigenesis and progression of PCa, but the functional underlying mechanism has not been studied clearly. We detected the expression level of SNHG12 in PCa tissues and matched adjacent normal tissues that were collected from 85 patients. Then, colony formation assays, MTT experiments, and flow cytometry were used to examine the effect of SNHG12 on proliferation, cell cycle distribution, and apoptosis of DU145 cells. Further, Transwell invasion assay was utilized to assess whether SNHG12 participates in PCa cell invasion and affects the secretion of VEGF secretion in DU145 cells. Finally, we investigated the effect of SNHG12 on tumor growth in vivo. We found that SNHG12 promoted cell proliferation and suppressed apoptosis in PCa cells, which suggests that SNHG12 is probably a novel PCa biomarker and therapy target of PCa.

1. Background

Prostate cancer (PCa) is the second most frequent diagnosis male malignancies and the leading cause of death worldwide [1, 2]. In China, PCa is one of the top ten leading causes of cancer-related death among men, and the morbidity and mortality rates of PCa are increasing annually rapidly, which is a serious risk to men’s life [3–6]. Even with the medical condition improving, the 5-year survival rate of PCa patients is still low [3, 6]. Therefore, further studying the mechanism underlying the pathogenesis and progression of PCa is very important and necessary.

Previous epidemiology of PCa studies have shown that the pathogenesis of PCa is closely associated with age, heredity, diet, environment, sex hormones, and epigenetic changes [7, 8]. Changes in epigenetics have been increasingly recognized as important factors in the occurrence and development of PCa [9, 10]. The most common epigenetic changes include the dysregulation of long noncoding RNAs (lncRNAs) [11], which are transcribed by RNA polymerase II and have more than 200 nucleotides without protein-coding ability [12]. For instance, the lncRNA CCAT1 promoted PCa cell proliferation by interacting with DDX5 and miR-28-5p [13]. Knockdown of lncRNA SNHG7 inhibited epithelial-mesenchymal transition in PCa through the miR-324-3p/WNT2B axis in vitro [14]. High lncRNA FEZF1-AS1 expression promoted cell proliferation and metastasis through Notch signaling in PCa [15]. Therefore, understanding the effects of lncRNAs on PCa could help identify novel diagnostic and therapeutic targets [16, 17].

Recently, lncRNAs have been found to be closely associated with tumorigenesis, growth, progression, and metastasis, as they act as gene regulators via transcriptional pathways [18]. For instance, lncRNA host gene 12 (SNHG12)
is considered a potential therapeutic target and biomarker of various human cancers, which is upregulated in gastric cancer, non-small cell lung cancer, triple negative breast cancer, and so on [19–21]. Recently, SNHG12 was reported to promote cell proliferation and accelerate tumorigenesis of PCa [22, 23]. However, effects of SNHG12 on the tumorigenesis and progression of PCa have not been studied clearly, and the mechanism underlying SNHG12 promote PCa cell proliferation needs to be further investigated.

Our study investigated whether SNHG12 exerts strong oncogenic effects during the progression of PCa cells. To this end, we explored (i) the effects of SNHG12 on PCa cell proliferation, cell cycle progression, and apoptosis; (ii) the underlying mechanism; and (iii) the impact of SNHG12 on angiogenic tube formation and vascular endothelial growth factor (VEGF) secretion in a human PCa cell line (i.e., DU145). Our results suggested that SNHG12 could be a novel molecular biomarker for PCa and provide a possible clinical therapeutic strategy for PCa.

2. Materials and Methods

2.1. Patients and Tissue Samples. Eighty-five pairs of PCa samples and control samples (i.e., matched normal prostate tissues) were derived from patients (N = 85) of primary PCa who underwent surgery at the Department of Urology of the First Affiliated Hospital of Jinan University and the Sixth People’s Hospital Affiliated with Shanghai Jiao Tong University. The samples were washed with sufficient cold phosphate-buffered saline (PBS) to reduce blood contamination and were then immediately placed in liquid nitrogen until for further experiments.

The patient was selected if he/she (i) was preoperatively diagnosed as low-risk PCa according to NCCN guidelines (PSA ≤ 10 ng/ml, GS score ≤ 6, T ≤ T2a) [18] and thus not diagnosed as adenocarcinoma of PCa or specific pathological types of PCa (e.g., ductal cancer, lymphoma, endocrine cancer of the prostate, and sarcoma), (ii) had punctured at least 8 stitches during the surgery when samples were taken, (iii) had not received endocrine therapy, radiotherapy, or chemotherapy, (iv) had no surgical contraindications or other types of tumors and not received radical PCa surgeries before this operation, and (v) had complete records of preoperative case data. All the above criteria should be met for each selected patient.

The protocol was approved by the Ethic Committee (Clinical Management Committee) of the First Affiliated Hospital of Jinan University, the Sixth People’s Hospital Affiliated with Shanghai Jiao Tong University and complied with world Medical Association Declaration of Helsinki. Written informed consents were obtained from all patients.

2.2. Cell Culture. The human prostate matrix immortalized WPMY-1 cells and human prostate cancer cell lines LNCAP, DU145, and PC-3 were purchased from the American Type Culture Collection (ATCC) and were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA) and 2 mmol/l L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. All cell lines were maintained under standard cell culture conditions at 37 °C in an incubator with 5% CO2 and 95% air and were passaged with 0.25% trypsin (Sigma, USA) for digestion and subculture when the cells were approximately 90% confluent. Additionally, the certificate of cell authentication is provided in the supplementary material.

2.3. Lentiviral shRNA-Mediated Knockdown. Lentiviral shRNA plasmids with microRNA scaffolds (Neuron Biotech, Shanghai, China) targeting human SNHG12 (hereafter referred to as lent-EGFPLetSNHG12-miR plasmids) or containing scrambled shRNA (hereafter referred to as lent-EGFP plasmids) were constructed. Cells (at a density of 1.0 × 105/ml) were cultured in 2 ml medium without antibiotics in 6-well plates. When the cells were ~80% confluent, the above-mentioned plasmids were transfected into cells using Lipofectamine 2000 (Invitrogen) together with gag/pol packaging vectors and VSVG-encoding plasmids to produce lentiviruses according to the manufacturer’s recommendations. Moreover, the multiplicity of infection (MOI) of lentivirus plasmids in target cells was 10. A volume of 5 µl of Lipofectamine 2000 was diluted with 250 µl of serum-free medium (Opti-MEM, Gibco, Invitrogen, USA), incubated for 5 min at room temperature, and swirled gently to mix evenly, after which the plasmids described above were added; this mixture was then incubated for 20 min at room temperature. The mixture was eventually added to the cell culture plates, which were incubated at a temperature of 37 °C in a humidified incubator with 95% O2 and 5% CO2. After an additional 6–8 h incubation, the mixture was replaced by complete medium, and the cells were incubated for 24–48 h.

2.4. Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) Detection. The total RNA of tumor tissue samples and cultured cells was extracted using TRIzol reagent (TIANGEN, China) in accordance with the manufacturer’s instructions. The RNA preparations were then cleared of genomic DNA contaminants by DNase treatment (Thermo, USA). Then, the concentration and purity of the RNA samples were assessed by spectrophotometrically determining the optical density ratio, and single-strand complementary DNA (cDNA) was synthesized from 0.5 µg of total RNA using a PrimeScript RT reagent kit (Takara, Japan) according to a standard protocol. Quantitative analysis of SNHG12 was performed on a 7500 Fast Real-time PCR system (Applied Biosystems, USA) using a SYBR® Premix Ex Taq™ II (TliRNaseH Plus) kit according to the manufacturer’s manual with 0.1 µg cDNA. The PCR temperature conditions were as follows: 1 cycle of denaturing at 95 °C for 30 s, 40 cycles of denaturing at 95 °C for 5 s, annealing at 60 °C for 34 s (with data collection at the end of the 60 °C step at each cycle), and dissociation at 95 °C for 15 s, 60 °C for 1 min, and 95 °C for 15 s. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control to normalize the SNHG12 quantitative data, which were further calculated with the 2^−ΔΔCt method. The sequences of the primers used for qRT-PCR were as follows: SNHG12, 5'-TCTGGGTGAT CGAGGACTTCC-3' (forward) and 5'-ACCTCTCTCAGT CGACAGCGG-3' (reverse).
ATCACACACT-3' (reverse); GAPDH, 5'-ACACCCACTCC TCCACCTTT-3' (forward) and 5'-TTACTCCTGGAGG CCATG-3' (reverse).

2.5. Western Blot Analysis. After collection, the cells were lysed in lysis buffer (Beyotime, Shanghai, China) supplemented with a “cocktail” of phenylmethylsulfonyl fluoride, phosphatase inhibitor, and protease inhibitor. The protein concentration of each sample was measured using the BCA protein assay kit (Pierce Biotechnology, USA) following the manufacturer’s guidelines. Then, equivalent quantities of protein (30 μg) were separated on 8–15% discontinuous SDS-polyacrylamide gels for electrophoresis (SDS-PAGE) and transferred onto nitrocellulose (NC) blotting membranes. The membranes were blocked with 10% skim milk for 2 h at room temperature and incubated overnight at 4°C with the appropriate primary antibodies. The membranes were then washed and further incubated with secondary antibodies (horseradish peroxidase conjugated) at room temperature for 1 h. The secondary antibodies were visualized with an enhanced chemiluminescence (ECL) system (Pierce Biotechnology, Rockford, IL). The band grayscale and the ratio of the band intensity of each protein of interest to those of the loading control were detected with the Adobe Photoshop software.

2.6. Colony Formation Assay. Cell monolayers were dissociated into single cells, which were then seeded into 6-well plates at a density of 500 cells/well in triplicate wells 4 days after transfection. After the fourteenth passage, the cells were fixed in methanol and stained with 0.5% crystal violet. The colony formation rate was calculated by dividing the number of colonies by the number of seeded cells.

2.7. Flow Cytometry Assay. For flow cytometry, cells in the logarithmic growth phase were harvested by trypsinization one week after lentivirus infection, fixed in 70% (v/v) ethanol overnight at -20°C, and then incubated with 50 μg/ml propidium iodide (PI, Sigma-Aldrich) and 50 μg/ml RNase A (Fermentas) for 30 min at room temperature in the dark. The stained nuclei were analyzed using a FACSCalibur flow cytometer with acquisition of 10,000 gated events. The DNA histograms were analyzed with the Flow software.

2.8. Transwell Invasion Assay. The frozen Matrigel at -20°C was dissolved at 4°C one day before the invasion experiment. On the second day, before gluing, 100 μl PBS was added to the chamber, and it was left at room temperature for 30 min to fully soak the chamber. After the PBS was sucked out, it was dried naturally in the safety cabinet for about 20 min. 30 μl diluted (1:5) glue was added into the chamber, and it was placed at 4°C for 1 h to balance. Then, the board with the chamber was incubated at 37°C for 4 h to allow the glue to solidify. Cells were digested with trypsin, centrifuged, and resuscitated in DMEM medium, cell count was performed, and cell concentration was adjusted to 4x10^5/ml. Cell suspension of 0.1 ml was added to the compartment, and 0.6 ml was added to complete culture based on the lower well. The chamber was carefully placed into the orifice plate with medium with tweezers (avoid bubbles at the bottom), and it was placed in the incubator. The migration situation was observed every day, and the culture was generally stopped at 48 h. The compartment was removed, the supernatant was removed from the compartment, and the cells in the upper compartment were carefully wiped off with a wet cotton swab. At room temperature, the cells were slightly washed with PBS, 0.5 ml 4% paraformaldehyde was absorbed into a clean hole, it was put into a small chamber, and it was fixed at room temperature for 15 min. The invaded cells were the mean value of separate 6 fields, and the magnification times were of 100 folds.

2.9. Vasculogenic Tube Formation Assay. Vasculogenic tube formation assays were performed as previously described [24]. Briefly, DU145 cells (3 × 10^4 cells), which are resuspended in 500 μl of EBM-2 with 2% FBS, were seeded in 24-well cell culture plates ( precoated with 100 μl of Matrigel) and incubated for 22 h at 37°C. The tubes (closed areas surrounded by cells) were quantified with the Wimasis Image Analysis software by averaging the number of loops from four separate 20 × fields.

Table 1: The clinicopathological information of recruited cases.

| Variable                          | Total no. (%) |
|----------------------------------|---------------|
| No. of cases                      | 85            |
| Median age (y, range)             | 66 (47-85)    |
| Median PSA (ng/ml, range)         | 7.84 (1.80-10.00) |
| Median FPSA (ng/ml, range)        | 0.87 (0.12-1.89) |
| Biopsy Gleason sum, n ≤6          | 85 (100%)     |
| AJCC-T stage, n                   |               |
| T1c                               | 0 (0%)        |
| T2a                               | 36 (42.35%)   |
| T2b                               | 24 (28.24%)   |
| T2c                               | 25 (29.41%)   |
| T3                                | 0 (0%)        |
| Pathological Gleason sum, n ≤6    | 62 (72.94%)   |
| 3+4                              | 12 (14.12%)   |
| 4+3                              | 11 (12.94%)   |
| ≥8                               | 0 (0%)        |
| Surgical margin, n                |               |
| Negative                          | 80 (94.12%)   |
| Positive                          | 5 (5.88%)     |
| Lymph node invasion, n            |               |
| Negative                          | 83 (97.65%)   |
| Positive                          | 2 (2.35%)     |
| Biochemical recurrence, n         | 7 (8.24%)     |
| Clinical progression, n           | 2 (2.35%)     |
| Follow-up months, median (range)  | 48 (8-96)     |

Follow-up months, median (range)
2.10. VEGF Secretion Assessment. VEGF release was assessed by a human-specific VEGF Quantikine ELISA Kit (R&D Systems, USA) according to the manufacturer’s protocol.

2.11. In Vivo Tumorigenesis Assay. The treated DU145 cells (1 × 105 cells/3 μl of DMEM) were injected into three groups of mice: (i) the DU145 group (no treatments, N = 20), (ii) the DU145-lenti-EGFP group (DU145 cells transected with lenti-EGFP lentivirus, N = 58), and (iii) the DU145-lenti-EGFP-SNHG12-miR group (DU145 cells transfected with lenti-EGFP-SNHG12-miRLentivirus, N = 58). These cells were subcutaneously injected into the posterior flanks of 6-week-old male nude mice, and the tumor diameters were measured every three days. The tumor volume was calculated as the length × width² × 1/2 mm3. The mice were sacrificed by CO2 inhalation to ameliorate animal suffering, and the tumors were collected and weighed. The protocol was approved by the Ethic Committee of the First Affiliated Hospital of Jinan University and the Sixth People’s Hospital Affiliated with Shanghai Jiao Tong University, following the Committee Guidelines on the Use of Live Animals in Research and the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

2.12. Statistical Analysis. Statistical analysis was performed using the SPSS 20.0 software (IBM SPSS, USA), and all experiments were performed at least three times to ensure the accuracy of the experiment. The tumor volumes are expressed as the mean ± standard error of the mean (SEM), and all the other values are expressed as the mean ± SD. Student’s t-test or nonparametric Mann–Whitney U test was conducted to analyze the differences between the 2 groups, and multiple comparisons were assessed by one-way analysis of variance (ANOVA) followed by a Bonferroni post hoc test. A two-sided P value less than 0.05 indicated a statistically significant difference.

3. Results

3.1. SNHG12 Was Upregulated in PCa Tissues and Cell Lines. The expression level of SNHG12 were determined in PCa tissues and matched normal adjacent tissues from 85 patients (Table 1). We found that the expression of SNHG12 in PCa tissues was significantly higher than that in matched normal adjacent tissues (P < 0.05) (Figure 1(a)). The gene expression level of SNHG12 in several PCa cell lines (DU145, LNCAP, and PC-3) and normal human prostate stromal cell line (WPMY-1) was detected by qRT-PCR. We found that SNHG12 was significantly upregulated in the DU145 cell line compared with the normal human prostate stromal cell line (WPMY-1) and the other two human prostate carcinoma cell lines, LNCAP and PC-3 (Figure 1(b)). Therefore, we chose the DU145 carcinoma cell line as an in vitro model for functional study of SNHG12.

3.2. Knockdown of SNHG12 Inhibited Proliferation of PCa Cells. Our results indicated that SNHG12 knockdown suppressed PCa cell proliferation and cell cycle progression. To investigate the function of SNHG12 in the proliferation of PCa cells, DU145 cells were transduced with lentiviral shRNA targeting the human SNHG12 gene (Figure 2(a)). Compared to the control group, the colony formation ability of DU145 cells was significantly decreased with SNHG12 knockdown (Figure 2(b)). The MTT assay showed that DU145 cell viability was also reduced by SNHG12 knockdown (Figure 2(c)). The cell cycle analysis of DU145 cells treated with knockdown of SNHG12 was performed by flow cytometry. Compared with the control group and the DU145+lenti-EGFP group, fewer DU145 cells transfected with lenti-EGFP-SNHG12-miR were in the G0/G1 phase, but more cells were in the S phase in the control group than in the SNHG12 knockdown group. The portion of DU145 cells in G2/M phase have no difference between the control group and the SNHG12 knockdown group (Figures 2(d) and 2(e)).
3.3. Knockdown of SNHG12 Promoted Early Apoptosis of PCa Cells.
The function of SNHG12 in PCa cell apoptosis was analyzed by flow cytometry technique. Early apoptosis ration of DU145 cells in the SNHG12 knockdown group were significantly higher than that in control group, whereas the late apoptosis ratio of DU145 cells have no difference among the

![Graphs and images related to the text content]

Figure 2: Negative effects of SNHG12 knockdown on the proliferation of PCa cells, as shown by SNHG12 expression (a), colony formation abilities (b), MTT assays (c), cell cycle progression (d), and the associated statistical results (e) for three experiment groups: the control group (DU145 cells), empty vector group (DU145 cells transduced with lenti-EGFP), and SNHG12 knockdown group (DU145 cells transduced with lenti-EGFP-sngh12-miR). The data are reported as the mean ± SD. **P < 0.01, ***P < 0.005, and ****P < 0.0001 compared with the control group (Student’s t-test).
Figure 3: Positive effects of SNHG12 knockdown on early apoptosis, as demonstrated by flow cytometric analysis (a), and the associated statistical results (b) for the three experiment groups: the control group (DU145 cells), empty vector group (DU145 cells transduced with lenti-EGFP), and SNHG12 knockdown group (DU145 cells transduced with lenti-EGFP-snhg12-miR). The data are reported as the means ± SD. The symbol “∗” indicates there is a significant difference between the pair of experiments (Student’s t-test, P < 0.05).

Figure 4: Significant negative effect of SNHG12 knockdown on cell invasion, as determined by the Transwell invasion analysis (scale bar, 100 μm) (a), and the associated statistical results (b) for the three experiment groups: the control group (DU145 cells), empty vector group (DU145 cells transduced with lenti-EGFP), and SNHG12 knockdown group (DU145 cells transduced with lenti-EGFP-snhg12-miR). *** P < 0.0001 compared with the control group (Student’s t-test).
three groups. The results suggested that knockdown of SNHG12 significantly increased early apoptosis ratio of DU145 cells (Figures 3(a) and 3(b)).

3.4. SNHG12 Promoted PCa Cell Invasion. To further clarify the function of SNHG12 in the PCa cell invasion, we used a Transwell invasion assay. The Transwell invasion assay showed that the number of DU145 cells that migrated from the upper chamber to the lower chamber was markedly lower in the group stably transfected with lenti-EGFP-SNHG12-miR than in the untreated group or the group transduced with lenti-EGFP (\(P < 0.0001\); Figures 4(a) and 4(b)).

3.5. SNHG12 Might Have Affected Angiogenesis Tube Formation by PCa Cells. The effect of SNHG12 on vasculo-geic tube formation was investigated. There were no significant differences in tube formation among the three groups (\(P > 0.05\); Figures 5(a) and 5(b)). However, knockdown of SNHG12 significantly downregulated the expression of VEGF (Figure 5(c)). These results suggest that SNHG12 had no obvious effect on vasculogenic tube formation in prostate tumors but negatively affect secretion of VEGF.

3.6. SNHG12 Affected the Expression of Apoptosis-Related and Invasion-Related Proteins. The protein levels of the apoptosis-related molecules Bax, Bcl-2, cleaved caspase-3, and the cell invasion-related molecule MMP-9 were determined. Our western blot analysis indicated that the expression of cleaved caspase-3 was significantly upregulated in
DU145 cells with SNHG12 knockdown ($P < 0.05$), although the expression of bcl-2 did not differ significantly among the three groups ($P > 0.05$; Figure 6(a)). In contrast, MMP-9 was markedly downregulated in the group of DU145 cells transfected with lenti-EGFP-SNHG12-miR compared with the other two groups ($P < 0.05$; Figure 6(b)). The PI3K/AKT signaling pathway plays a pivotal role in the invasiveness of PCa cells. Therefore, we also evaluated the effect of SNHG12 on AKT phosphorylation. Additionally, SNHG12 knockdown inhibited the expression of phosphorylated AKT (Figure 6(b)), although total AKT was not significantly different in the three groups (Figure 6(c)). The above-mentioned results suggested that SNHG12 knockdown suppressed the invasiveness of PCa cells via upregulating caspase-3 and downregulating MMP-9 and phosphorylated AKT.
3.7 SNHG12 Knockdown Inhibited Tumor Growth In Vivo.
To further investigate the effect of SNHG12 on PCa in vivo, we established a nude mouse xenograft model with DU145 cells. DU145 cells were stably transfected with lenti-EGFP or lenti-EGFP-SNHG12-miR. Transfected cells or wild-type DU145 cells were subcutaneously inoculated into nude mice (N = 20 in DU145 group and N = 58 in DU145+lenti-EGFP or DU145+lenti-EGFP-SNHG12-miR groups). We found that body weights of nude mice were not significantly affected by the injection of DU145 cells (P > 0.05; Figure 7(a)). However, SNHG12 knockdown significantly inhibited tumor growth on the 28th day after inoculation (P < 0.05; Figure 7). Twenty-eight days after inoculation, the tumor weights and tumor sizes were significantly smaller in mice inoculated with DU145-lenti-EGFP-SNHG12-miR cells than in mice inoculated with wild-type DU145 cells or negative control DU145-lenti-EGFP cells (both P < 0.05; Figures 7(b)–7(d)). The results from the in vivo assay demonstrated that SNHG12 knockdown dramatically inhibited tumor growth.

4. Discussion
Our study provides novel knowledge about the mechanism of how a lncRNA, SNHG12, is associated with PCa. Compared with previous similar studies [22, 23], we detected SNHG12 levels in tissues from PCa patients tissues and three PCa-derived-associated cells (LNCAP, DU145, and PC-3) as well as myoﬁbroblast stromal cell line (WPMY-1 cells), by qRT-PCR. We revealed that there was a significant increase in SNHG12 expression in clinical PCa tissues and DU145 cells compared to matched normal adjacent tissues from patients and other cell lines investigated, which was in line with previous findings [23]. Upregulated SNHG12 expression has been reported in various other cancers, such as cervical cancer [21], hepatocellular carcinoma [24], and others [20]. Therefore, our findings support the idea that SNHG12 might be an oncogenic molecule in the development of these cancers, including PCa. SNHG12 can be a potential prognostic and diagnostic biomarker in PCa patients.
Our results of the MTT assay and colony formation assay showed that SNHG12 knockdown inhibited proliferation and cell cycle progression in PCa cells, in line with a recent study on PCA [22] and other cancer studies such as hepatocellular carcinoma [20, 24]. Uncontrolled cell proliferation and a dysfunctional cell cycle are key features during the tumorigenesis process of PCa [1], as of many other cancers [25]. It has also been confirmed that SNHG12 promotes the proliferation glioma cells by binding to HuR [26] and SNHG12 increases the expression of cell cycle-related proteins to accelerate cell growth in colorectal cancer [27]. In addition, the flow cytometry results showed that knockdown of SNHG12 expression significantly promoted early apoptosis in DU145 cells and upregulated the caspase-3, suggesting that knockdown of SNHG12 induced cell early apoptosis through the caspase signaling pathway, which is consistent with the functions of SNHG12 in NSCLC cells [28]. Previous studies have already reported that metastasis of cancer cells is the main cause of treatment failure in most patients with advanced cancer, and invasion is the first step that triggers cancer metastasis [29]. Herein, SNHG12 knockdown markedly suppressed PCa cell invasiveness and downregulated the expression of the invasion-related protein MMP-9, which suggested that SNHG12 promoted the DU145 invasion and probably participated in the metastasis of PCa. Additionally, angiogenesis is also a major factor that promotes tumor formation, as angiogenesis can provide better nutrition for tumor cells to promote their growth. Interestingly, we found that knockdown of SNHG12 had no evident effect on vasculogenic tube formation in DU145 cells despite the fact that it could remarkably decrease secretion of VEGF, which is molecular playing a critical role in angiogenesis. The in vivo xenograft experiment demonstrated that SNHG12 knockdown inhibited prostate tumor growth. The above-mentioned results indicated that SNHG12 can be a potential therapy target in the treatment of PCa.

Our results indicated that the AKT pathway was positively regulated by SNHG12, as found in studies of renal cell carcinoma [30]. Herein, downregulation of p-AKT expression was evident upon SNHG12 knockdown in DU145 cells. Similar downregulation of p-AKT after SNHG12 knockdown was also observed in studies of gastric cancers [31]. SNHG12 may promote PCa cell proliferation and cell cycle progression by activating the PI3K/AKT signaling pathway, the detailed mechanism requires further investigation.

In conclusion, our study demonstrated that SNHG12 was upregulated in PCa tissues and cells, and knockdown of SNHG12 inhibited the proliferation and invasion of PCa cells and suppressed the PCa growth which provided new evidence that SNHG12 could be a valuable biomarker for PCa diagnosis and prognosis and a potential target for PCa gene therapy. We encourage future studies to uncover more detailed mechanisms of the SNHG12 as a regulator of PCa and other cancers.

Data Availability

All data, models, and code generated or used during the study appear in the submitted article.

Conflicts of Interest

The authors have declared that no competing interest exists.

Acknowledgments

This work was supported by the Natural Science Foundation of China (81902615), Postdoctoral Fund of the First Affiliated Hospital, Jinan University (809011), Postdoctoral Program of the International Training Program for Outstanding Scientific Research of Guangdong Province (2019), and Leading Specialist Construction Project-Department of Urology, the First Affiliated Hospital, Jinan University (711006). The manuscript was previously submitted on a preprint server, but it was rejected after peer-review. Now, neither the entire paper nor any part of its content has been published or being considered for publication elsewhere. It is not being submitted to any other journal. All authors agree to submit the work to Biomed Research International. We also agree to transfer the copyright of the paper to the publisher.

References

[1] L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, "Global cancer statistics, 2012,” CA: a Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015.
[2] T. Kimura and S. Egawa, "Epidemiology of prostate cancer in Asian countries,” International Journal of Urology, vol. 25, no. 6, pp. 524–531, 2018.
[3] W. Chen, R. Zheng, P. D. Baade et al., "Cancer statistics in China, 2015,” CA: a Cancer Journal for Clinicians, vol. 66, no. 2, pp. 115–132, 2016.
[4] F. Pishgar, H. Ebrahimi, S. Saeedi Moghaddam, C. Fitzmaurice, and E. Amini, "Global, regional, and national burden of prostate cancer, 1990 to 2015: results from the global burden of disease study 2015,” Journal of Urology, vol. 199, no. 5, pp. 1224–1232, 2018.
[5] S. C. Ren, R. Chen, and Y. H. Sun, "Prostate cancer research in China,” Asian Journal of Andrology, vol. 15, no. 3, pp. 350–353, 2013.
[6] D. Liu, Y. Kuai, R. Zhu et al., "Prognosis of prostate cancer and bone metastasis pattern of patients: a SEER-based study and a local hospital based study from China,” Scientific Reports, vol. 10, no. 1, p. 9104, 2020.
[7] S. F. Peisch, E. L. Van Blarigan, J. M. Chan, M. J. Stampler, and S. A. Kenfield, "Prostate cancer progression and mortality: a review of diet and lifestyle factors,” World Journal of Urology, vol. 35, no. 6, pp. 867–874, 2017.
[8] R. C. Reulen, S. de Vogel, W. Zhong et al., "Physical activity and risk of prostate and bladder cancer in China: the South and East China case-control study on prostate and bladder cancer,” PLoS One, vol. 12, no. 6, article e0178613, 2017.
[9] S. Yegnasubramanian, "Prostate cancer epigenetics and its clinical implications,” Asian Journal of Andrology, vol. 18, no. 4, pp. 549–558, 2016.
[10] Y. Wu, M. Sarkissyan, and J. V. Vadgama, "Epigenetics in breast and prostate cancer,” Methods in Molecular Biology, vol. 1238, pp. 425–466, 2015.
[11] A. Misawa, K. I. Takayama, and S. Inoue, "Long non-coding RNAs and prostate cancer," Cancer Science, vol. 108, no. 11, pp. 2107–2114, 2017.
[12] J. J. Quinn and H. Y. Chang, "Unique features of long non-coding RNA biogenesis and function," Nature Reviews Genetics, vol. 17, no. 1, pp. 47–62, 2016.
[13] Z. You, C. Liu, C. Wang et al., "LncRNA CCAT1 promotes prostate cancer cell proliferation by interacting with DDX5 and miR-28-5p," Molecular Cancer Therapeutics, vol. 18, no. 12, pp. 2469–2479, 2019.
[14] Y. Han, H. Hu, and J. Zhou, "Knockdown of LncRNA SNHG7 inhibited epithelial-mesenchymal transition in prostate cancer though miR-324-3p/WNT2B axis in vitro," Pathology Research and Practice, vol. 215, no. 10, article 152537, 2019.
[15] L. F. Zhu, L. D. Song, Q. Xu, and J. F. Zhan, "Highly expressed long non-coding RNA FEZF1-AS1 promotes cells proliferation and metastasis through Notch signaling in prostate cancer," European Review for Medical and Pharmacological Sciences, vol. 23, no. 12, pp. 5122–5132, 2019.
[16] V. Mouraviev, B. Lee, V. Patel et al., "Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer," Prostate Cancer and Prostatic Diseases, vol. 19, no. 1, pp. 14–20, 2016.
[17] A. Zhang, J. Zhang, A. Kaipainen, J. M. Lucas, and H. Yang, "Long non-coding RNA: a newly deciphered "code" in prostate cancer," Cancer Letters, vol. 375, no. 2, pp. 323–330, 2016.
[18] J. Beermann, M. T. Piccoli, J. Viereck, and T. Thum, "Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches," Physiological Reviews, vol. 96, no. 4, pp. 1297–1325, 2016.
[19] H. Zhang and W. Lu, "LncRNA SNHG12 regulates gastric cancer progression by acting as a molecular sponge of miR-320," Molecular Medicine Reports, vol. 17, no. 2, pp. 2743–2749, 2018.
[20] S. Tamang, V. Acharya, D. Roy et al., "SNHG12: an lncRNA as a potential therapeutic target and biomarker for human cancer," Frontiers in Oncology, vol. 9, p. 901, 2019.
[21] X. J. Jin, X. J. Chen, Z. F. Zhang et al., "Long noncoding RNA SNHG12 promotes the progression of cervical cancer via modulating miR-125b/STAT3 axis," Journal of Cellular Physiology, vol. 234, no. 5, pp. 6624–6632, 2019.
[22] J. Song, X. Wu, R. Ma, L. Miao, L. Xiong, and W. Zhao, "Long noncoding RNA SNHG12 promotes cell proliferation and activates Wnt/β-catenin signaling in prostate cancer through sponging microRNA-195," Journal of Cellular Biochemistry, vol. 120, no. 8, pp. 13066–13075, 2019.
[23] G. Cheng, Z. Song, Y. Liu et al., "Long noncoding RNA SNHG12 indicates the prognosis of prostate cancer and accelerates tumorigenesis via sponging miR-133b," Journal of Cellular Physiology, vol. 235, no. 2, pp. 1235–1246, 2020.
[24] T. Lan, W. Ma, Z. Hong, L. Wu, X. Chen, and Y. Yuan, "Long non-coding RNA small nucleolar RNA host gene 12 (SNHG12) promotes tumorigenesis and metastasis by targeting miR-199a/b-5p in hepatocellular carcinoma," Journal of Experimental & Clinical Cancer Research, vol. 36, no. 1, p. 11, 2017.
[25] M. Malumbres and M. Barbacid, "Cell cycle, CDKs and cancer: a changing paradigm," Nature Reviews Cancer, vol. 9, no. 3, pp. 153–166, 2009.
[26] W. Lei, Z. L. Wang, H. J. Feng, X. D. Lin, C. Z. Li, and D. Fan, "Long non-coding RNA SNHG12 promotes the proliferation and migration of glioma cells by binding to HuR," International Journal of Oncology, vol. 53, no. 3, pp. 1374–1384, 2018.
[27] J. Z. Wang, C. L. Xu, H. Wu, and S. J. Shen, "LncRNA SNHG12 promotes cell growth and inhibits cell apoptosis in colorectal cancer cells," Brazilian Journal of Medical and Biological Research, vol. 50, no. 3, article e6079, 2017.
[28] Y. Wang, S. Liang, Y. Yu, Y. Shi, and H. Zheng, "Knockdown of SNHG12 suppresses tumor metastasis and epithelial-mesenchymal transition via the Slug/ZEβ2 signaling pathway by targeting miR-218 in NSCLC," Oncology Letters, vol. 17, no. 2, pp. 2356–2364, 2019.
[29] J. Robert, "Biology of cancer metastasis," Bulletin du Cancer, vol. 100, no. 4, pp. 333–342, 2013.
[30] Y. Liu, G. Cheng, Z. Huang et al., "Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma," Cell Death & Disease, vol. 11, no. 7, p. 515, 2020.
[31] Y. Zhao, Q. Dong, and E. Wang, "MicroRNA-320 inhibits invasion and induces apoptosis by targeting CRKL and inhibiting ERK and AKT signaling in gastric cancer cells," Oncotargets and Therapy, vol. 10, pp. 1049–1058, 2017.